Correction for Chan et al., "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge".
Correction for Chan et al., "A Novel, Multiple-Antigen Pneumococcal Vaccine Protects against Lethal Streptococcus pneumoniae Challenge".
复制标题
对 Chan 等人的更正，“一种新型多抗原肺炎球菌疫苗可防止致命的肺炎链球菌挑战”。
DOI：
10.1128/iai.00639-21
复制
发表时间：
2022
影响因子：
3.1
通讯作者：
Chan WY
中科院分区：
文献类型：
--
作者：
Chan WY
第87卷，第3号，e00846-18，2019，https：//doi。org/10.1128/IAI。00846-18.由于多抗原疫苗（MAV）制剂的其中一个批次（特别是MAV批次IPS 004 [MAVIPS 004]和MAVIPS 005的培养条件）的标签错误导致结果解释混淆，因此对文章摘要、材料和方法、结果和讨论进行了更正。MAVIPS 004和MAVIPS 005在30 ℃下培养，MAVIPS 004在进一步处理前也在37 ℃下培养一段时间.因此，这些产品的比较不能正确评估热休克对抗原性的影响。这两种产品的比较仍然是疫苗临床材料生产工艺开发的重要部分，需要比较MAVIPS 004和MAVIPS 005之间的抗原含量，以表明将培养温度降低至30 ℃不会影响MAV产品的抗原性。修正这些错误的手稿修订版正在同时出版（https：//doi. org/10.1128/iai。00846-18a）。
Volume 87, no. 3, e00846-18, 2019, https://doi. org/10.1128/IAI. 00846-18. Corrections in the Abstract, Materials and Methods, Results, and Discussion were made to the article since an error in labeling one of the batches of the multiple-antigen vaccine (MAV) preparations (specifically, the culture conditions for MAV batch IPS004 [MAVIPS004] and MAVIPS005) caused confusion about interpretation of the results. MAVIPS004 and MAVIPS005 were cultured at 30 C, with the MAVIPS004 also having a short period at 37 C before processing further. Hence, comparison of these products does not properly assess the effects of heat shock on antigenicity. The comparison of these two products remains an important part of the development of the production process for vaccine clinical material, with the comparison of the antigen content between MAVIPS004 and MAVIPS005 needed to show that reducing the culture temperature to 30 C did not affect the antigenicity of the MAV product. A revised version of the manuscript that corrects these errors is being published simultaneously (https://doi. org/10.1128/iai. 00846-18a).